Holen Sie sich die Stockscreener-App
319.07
1.82%
5.57
Schlusskurs vom Vortag:
$313.50
Offen:
$315.11
24-Stunden-Volumen:
315.29K
Relative Volume:
0.66
Marktkapitalisierung:
$8.88B
Einnahmen:
$7.46M
Nettoeinkommen (Verlust:
$-326.53M
KGV:
-23.85
EPS:
-13.3803
Netto-Cashflow:
$-282.53M
1W Leistung:
-4.65%
1M Leistung:
+25.67%
6M Leistung:
+9.08%
1J Leistung:
+583.83%
1-Tages-Spanne:
$307.00
$327.61
1-Wochen-Bereich:
$307.00
$337.72
52-Wochen-Spanne:
$37.19
$366.52
Praxis Precision Medicines Inc Stock (PRAX) Company Profile
Firmenname
Praxis Precision Medicines Inc
Sektor
Branche
Telefon
617-300-8460
Adresse
99 HIGH STREET, 30TH FLOOR, BOSTON
Compare PRAX vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PRAX
Praxis Precision Medicines Inc
|
318.40 | 8.74B | 7.46M | -326.53M | -282.53M | -13.38 |
VRTX
Vertex Pharmaceuticals Inc
|
522.41 | 134.41B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
672.79 | 68.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
915.98 | 57.01B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
320.29 | 41.79B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
190.13 | 40.39B | 742.00K | -1.37B | -1.07B | -7.0731 |
Praxis Precision Medicines Inc Stock (PRAX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-10 | Eingeleitet | Raymond James | Strong Buy |
| 2026-02-24 | Eingeleitet | Wolfe Research | Outperform |
| 2026-02-02 | Eingeleitet | Wells Fargo | Equal Weight |
| 2025-12-15 | Bestätigt | Oppenheimer | Outperform |
| 2025-11-19 | Eingeleitet | BTIG Research | Buy |
| 2025-06-02 | Fortgesetzt | Oppenheimer | Outperform |
| 2025-05-07 | Eingeleitet | Chardan Capital Markets | Buy |
| 2025-03-03 | Bestätigt | H.C. Wainwright | Buy |
| 2025-02-11 | Eingeleitet | Deutsche Bank | Buy |
| 2024-08-05 | Eingeleitet | Oppenheimer | Outperform |
| 2024-06-24 | Eingeleitet | Needham | Buy |
| 2024-06-18 | Eingeleitet | Guggenheim | Buy |
| 2024-05-01 | Eingeleitet | Robert W. Baird | Outperform |
| 2023-09-19 | Eingeleitet | Truist | Buy |
| 2022-06-06 | Herabstufung | Wedbush | Outperform → Neutral |
| 2021-12-16 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-08-26 | Eingeleitet | BofA Securities | Buy |
| 2021-04-26 | Eingeleitet | William Blair | Outperform |
| 2020-11-11 | Eingeleitet | Wedbush | Outperform |
| 2020-11-10 | Eingeleitet | Cowen | Outperform |
| 2020-11-10 | Eingeleitet | Evercore ISI | Outperform |
| 2020-11-10 | Eingeleitet | Piper Sandler | Overweight |
Alle ansehen
Praxis Precision Medicines Inc Aktie (PRAX) Neueste Nachrichten
Praxis Precision (PRAX) Partners with Remagine Labs for Innovati - GuruFocus
Praxis Precision Medicines and Remagine Labs Announce Strategic Collaboration to Develop Transdermal Ulixacaltamide for Essential Tremor - The Manila Times
Praxis bets on skin patch for essential tremor drug - Stock Titan
S&P 500 Futures Climb in Premarket Trading; Praxis Precision Meds, IREN Lead - Barron's
PRAX stock. Praxis Precision Medicines holds the spotlight on thin news - AD HOC NEWS
Praxis Precision Shares Rally On Price Target Hikes: Analyst Sees Upside As High As 100% For Stock - Stocktwits
Praxis Precision (NASDAQ: PRAX) replaces EY with KPMG as auditor - Stock Titan
Praxis uses inducement plan to grant 951 shares to five hires - Stock Titan
Price to sales forward of Praxis Precision Medicines, Inc. – NASDAQ:PRAX - TradingView
Enterprise value to revenue forward of Praxis Precision Medicines, Inc. – NASDAQ:PRAX - TradingView
Price to book forward of Praxis Precision Medicines, Inc. – NASDAQ:PRAX - TradingView
We Think Praxis Precision Medicines (NASDAQ:PRAX) Can Easily Afford To Drive Business Growth - Moomoo
LifeSci Capital Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Cuts Target Price to $719 - Moomoo
The Technical Signals Behind (PRAX) That Institutions Follow - Stock Traders Daily
Guggenheim Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Maintains Target Price $800 - Moomoo
Praxis sees encephalopathies asset relutrigine action date extended - MSN
PRAX Maintained by Needham -- Price Target Raised to $575 - GuruFocus
Price to earnings forward of Praxis Precision Medicines, Inc. – NASDAQ:PRAX - TradingView
Praxis Precision Medicines (PRAX) Surges Nearly 7% as Momentum BuildsVolatility Stop - dars.gov.et
Stocks to Watch: AeroVironment, Concentrix, Gain Therapeutics, Praxis Precision Medicines - Moomoo
Praxis Precision Medicines stock falls on FDA review delay By Investing.com - Investing.com South Africa
FDA Extends Review Timeline for Praxis’ Relutrigine NDA - TipRanks
Praxis Precision Medicines stock falls on FDA review delay - Investing.com UK
FDA extends Praxis (NASDAQ: PRAX) relutrigine review deadline to Dec 27, 2026 - Stock Titan
Praxis Precision Medicines Announces FDA Extends Review of Relutrigine NDA to December 27, 2026 - Quiver Quantitative
FDA delays Praxis relutrigine review by three months to Dec. 27 - Stock Titan
Praxis Precision Medicines, Inc.(NasdaqGS:PRAX) dropped from Russell Microcap Growth Benchmark Index - marketscreener.com
Praxis Precision Medicines, Inc.(NasdaqGS:PRAX) dropped from Russell Small Cap Comp Value Benchmark - marketscreener.com
Praxis Precision Medicines, Inc.(NasdaqGS: PRAX) dropped from Russell 3000E Index - marketscreener.com
Praxis Precision Medicines, Inc.(NasdaqGS:PRAX) dropped from Russell 3000E Growth Benchmark - marketscreener.com
Praxis Precision Medicines, Inc.(NasdaqGS:PRAX) dropped from Russell 3000 Value Benchmark - marketscreener.com
Praxis Precision Medicines, Inc.(NasdaqGS: PRAX) dropped from Russell Microcap Index - marketscreener.com
Praxis Precision Medicines, Inc.(NasdaqGS:PRAX) dropped from Russell 3000E Value Benchmark - marketscreener.com
Praxis Precision Medicines, Inc.(NasdaqGS:PRAX) dropped from Russell Microcap Value Benchmark Index - marketscreener.com
Praxis gains FDA breakthrough therapy status for elsunersen for encephalopathy - MSN
Praxis Precision Medicines director Jill DeSimone sells $3.6m in shares - Investing.com Nigeria
Praxis Precision Medicines(PRAX.US) Director Sells US$3.61 Million in Common Stock - Moomoo
Form 4 Praxis Precision Medicines Inc For: 26 June By Investing.com - Investing.com South Africa
Praxis Precision Medicines Insider Sold Shares Worth $3,611,335, According to a Recent SEC Filing - marketscreener.com
Praxis (PRAX) director logs 11,600-share sale after option exercises - Stock Titan
Praxis Precision Medicines Stock Surges 27%, With A 6-Day Winning Spree - Trefis
null - Trefis
Praxis Precision Medicines, Inc. Actuals & Estimates (BOATS:PRAX) - TradingView
Praxis Precision Medicines outlines next steps, shares trade quietly on Nasdaq - Ad-hoc-news.de
PRAX Forecast — Price Target — Prediction for 2027 - TradingView
Praxis Precision Medicines, Inc. (PRAX) Stock Price, Quote, News & Analysis - Seeking Alpha
Form 144 Praxis Precision Medicines For: 24 June By Investing.com - Investing.com Australia
Form 144 | Praxis Precision Medicines(PRAX.US) Director Proposes to Sell 3.61 Million in Common Stocks - Moomoo
[144] Praxis Precision Medicines, Inc. SEC Filing - Stock Titan
Praxis Precision Medicines (PRAX): Best Upside Stocks to Buy According to Hedge Funds - Insider Monkey
Praxis 'Strong Buy': PDUFA In Early 2027 For Ulixacaltamide And BTD Elsunersen (PRAX) - Seeking Alpha
Finanzdaten der Praxis Precision Medicines Inc-Aktie (PRAX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Praxis Precision Medicines Inc-Aktie (PRAX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| DeSimone Jill | Director |
Jun 24 '26 |
Sale |
311.32 |
11,600 |
3,611,335 |
2,337 |
1.21%
3.14%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):